[ad_1]
A recent study published in Nature Communications Medicine has demonstrated promising results for tinnitus patients using Lenire, an FDA-approved bimodal neuromodulation device. The research, which analyzed 220 individuals with moderate to severe tinnitus, found that 91.5% experienced clinically significant improvement after 12 weeks of treatment. These real-world outcomes align with earlier clinical trial data that supported the neuromodulation device’s regulatory approval in 2023.
Lenire’s approach to tinnitus treatment involves simultaneous auditory and tactile stimulation. The device delivers tailored sound frequencies through headphones while applying mild electrical pulses to the tongue via a proprietary electrode array. This dual-pathway stimulation is theorized to modulate overactive neural circuits associated with tinnitus perception.
Administered under audiologist supervision, the treatment requires two daily 30-minute sessions over several weeks, making the device a non-invasive, at-home alternative to existing management strategies.
Image Credit: Neuromod Devices
[ad_2]
Source link